Structure-Based Prototype Peptides Targeting the *Pseudomonas aeruginosa* Type VI Secretion System Effector as a Novel Antibacterial Strategy

Xiaopan Gao†, Zhixia Mu†, Bo Qin, Yicheng Sun* and Sheng Cui*

MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

The type VI secretion system (T6SS) secretes numerous toxins for bacteria-bacteria competition. TplE is a newly identified trans-kingdom toxin secreted by the T6SS in *Pseudomonas aeruginosa*, while TplEi neutralizes the toxic effect of TplE to protect bacteria autointoxication. Blocking the interaction of TplE-TplEi could unleash the toxin, causing bacterial cell death. In this study, we applied a crystallographic approach to design a structural-based antimicrobial peptides targeting the interaction of TplE and TplEi. We found that a peptide (designed as “L” peptide based on its shape) derived from TplE can form a crystal complex with TplEi after subtilisin treatment and the crystal structure was solved at 2.2Å. The “L” peptide displays strong binding affinity to TplEi in vitro and can release the TplE toxin to induce bacteria death in vivo. Our findings suggest that as a toxin activator, the “L” peptide could be a possible drug lead for treating *P. aeruginosa* infection. Our findings provide an example that the T6SS effector and immunity protein could be a potential drug target against bacteria infection.

Keywords: *Pseudomonas aeruginosa*, T6SS, effector-immunity, TplE-TplEi interaction, toxin-antitoxin, antibacterial peptide

INTRODUCTION

*Pseudomonas aeruginosa* is one of the most common nosocomial infectious bacteria that causes significant morbidity and mortality in immunocompromised patients or intensive care unit (ICU) patients (Oliver et al., 2015). *P. aeruginosa* strains has developed multidrug-resistant (MDR) or even extensively drug-resistant (XDR) phenotypes, which are resistant to most of the currently used antibiotics. Thus, it is an urgent need to develop novel effective antibacterial agents (Reardon, 2014).

The type VI secretion system (T6SSs) has recently garnered more attention than ever because of its widespread occurrence and significance in the ecosystem function and human health (Russell et al., 2014). T6SS is a versatile molecular machine deployed by many bacterial species to deliver protein effectors into both prokaryotic and eukaryotic cells. T6SS is typically encoded in large and variable gene clusters via 14 conserved “core” proteins essential for function and a variable complement of accessory elements (Shneider et al., 2013; Cianfanelli et al., 2016). Bioinformatics and structural evidence have shown that T6SS is believed to resembles a bacteriophage tail-like
structure, and the contraction of this device delivers multiple, diverse effector proteins directly into the recipient cells in a dynamic “firing” mechanism (Cianfanelli et al., 2016). The “firing” mechanism takes two forms. In the first form, the effectors are fused to structural components (“specialized” effectors) such as PAAR and VgrG proteins. In the second form, there is a noncovalent interaction with one of the core components (“cargo” effectors), such as Hcp1 and Tse2 of the H1-T6SS of *P. aeruginosa* (Silverman et al., 2013; Durand et al., 2014; Whitney et al., 2014).

*P. aeruginosa* encodes three distinct T6SS hemolysin coregulated protein (Hcp) secretion islands (named H1-to H3-T6SS) that act against both prokaryotic and eukaryotic cells (Shneider et al., 2013; Cianfanelli et al., 2016; Sana et al., 2016). Recently, considerable progress has been made in identifying the effectors of the *P. aeruginosa* T6SS, including cell-wall-targeting enzymes (Type VI amidase effectors named Tae and Type VI glycoside hydrolase effectors named Tge), cell membrane-targeting enzymes (Type VI lipase effectors name Tle), nucleases, and NAD(P) glycohydrolase effectors. These effectors participate in inter- and intra-species competition, and they are produced concomitantly with specific immunity proteins that neutralize cognate toxins to prevent autointoxication (Russell et al., 2011, 2012, 2013; Whitney et al., 2015). TplE, a novel H2-T6SS-dependent lipase effector, was recently identified (Jiang et al., 2016). TplE is an antibacterial lipolytic toxin andTplEi interacts with TplE to provide protection from TplE (Jiang et al., 2016). The crystal structure of the TplE and TplEi complex provided structural insights into the mechanism of TplE functioning as an antibacterial lipolytic toxin and TplEi functioning as an immunity protein (Lu et al., 2014). Disrupting the interaction between TplE and TplEi could release the toxin activity and cause bacterial cell death, prompting us to target the TplE-TplEi interaction for the development of novel antimicrobial agents.

Herein, we solved the crystal structure of TplEi in complex with a TplE peptide (residues 82-108) generated by treatment with subtilisin. The TplE peptide (denoted the “L” peptide) has a high binding affinity for TplEi in *vitro* and precludes the formation of the TplE-TplEi complex, which in turn releases the toxicity of TplE and thereby induces bacterial cell death. This is the first time that the T6SS effector is targeted as an antibacterial candidate, providing a proof of concept for the use of “L” peptides as possible drug leads for combating *P. aeruginosa* infection.

**MATERIALS AND METHODS**

**Construct Design, Protein Expression and Purification**

Plasmid-encoding TplEi and/or TplEi-TplE complex (pETDuet-1 vector with ORF1 encoding TplEi and ORF2 coding TplE) was transformed into *E. coli* strain Rosetta™(DE3) competent cells (Novagen) for expression. The bacterial cultures were grown in LB medium at 37°C. The induction was initiated by the addition of IPTG (0.2 mM for TplEi-TplE complex; 0.5 mM for TplEi alone) when the culture reached OD<sub>600</sub> = 1.2. The bacterial culture was incubated with shaking at 25°C overnight after the induction. The bacterial cells were then harvested by centrifugation (5,000 rpm, 30 min) and re-suspended in lysis buffer containing 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM imidazole and 4 mM β-mercaptoethanol and disrupted by ultrasonication on ice. The cell debris was removed by centrifugation at 13,000 rpm for 60 min. The clarified supernatant was loaded to Ni-NTA resin (Qiagen). The TplEi and/or TplEi-TplE complex was next loaded on a HitTrap Q HP column (GE Healthcare) and eluted with the linear gradient of 75–1,000 mM NaCl. Finally, the eluted proteins were concentrated and applied to a Superdex 200 HR 10/30 column (GE Healthcare) equilibrated with 20 mM Tris-HCl pH 8.0, 100 mM NaCl and 2 mM DTT. The selenomethionine-substituted TplEi-TplE complex was produced by expression in the *E. coli* methionine auxotrophic strain B834 (DE3) in LeMASTER medium containing L-selenomethionine. The purification procedure for the SeMet derivative was the same as that of the native protein.

**Crystallization and Structure Determination**

The crystallization experiments were performed using the hanging drop vapor diffusion setup at 22°C by mixing 1 µl of buffer and 1 µl of protein solution equilibrated over a 0.3 ml reservoir solution. Crystallization trials of TplEi alone and TplEi-TplE complex were subjected to *in situ* limited proteolysis by incubating trace amounts of trypsin and subtilisin from the Proti-ACE Kit (Hampton Research). The SeMet-labeled TplEi were grown in 0.52 M lithium sulfate, 13% PEG8000 after 48 h of incubation. The TplEi-TplE complex crystal appeared 1 month later at 22°C. The optimized condition for the TplEi-TplE complex was achieved by mixing 1 µl of buffer containing 0.1 M sodium HEPES, 20% (w/v) PEG 10,000 and 1 µl of protein solution with trace amounts of subtilisin. Crystals were soaked in reservoir solution supplemented with 10% ethylene glycol for 30–60 s before flash freezing in liquid nitrogen. X-ray diffraction experiments were conducted at beam line BL17U in Shanghai Synchrotron Radiation Facility (SSRF). All diffraction data were processed with the XDS package (Kabsch, 2010). The software program AUTO SHARP/SHARP was used to locate the Se atoms and to calculate the initial phase, producing an interpretable electron density map (Bricogne et al., 2003). The atomic model was built manually using the program Coot (Emsley and Cowtan, 2004) and was refined using PHENIX (Adams et al., 2010). The final model has excellent refinement statistics and stereochemistry quality. All of the structure figures were prepared using PyMOL (http://www.pymol.org).

**Peptide Synthesis**

The “L” peptide (TplE residues 82-108) and its mutants (Table S1) derived from a complex crystal structure between TplEi and TplE (residues 82-108) were synthesized using a standard solid-phase FMOC N-(9-fluorenylmethoxycarbonyl) method purchased from Sclight Biotechnology LLC, as previously described (Yao et al., 2012). All of the peptides were acetylated at the N-terminus and amidated at the C-terminus. Synthesized peptides were purified by reversed-phase high-performance liquid chromatography (HPLC) and verified for purity >98%
and correct amino acid composition by mass spectrometry. The peptides were freeze-dried into powder and dissolved at 4 mg/ml according to the production report for the stock solution.

**Isothermal Titration Calorimetry**

Isothermal titration calorimetry (ITC) assay was performed with a MicroCalTM iTC200 calorimeter (MicroCal, USA) at 25°C; both the protein and peptides were dissolved with the same buffer (20 mM Tris–HCl, pH = 8.0, 100 mM NaCl). The concentration ofTplEi was between 0.03 and 0.04 mM. The concentrations of wild type peptides and mutants were between 1 and 2 mM. Titration was scheduled with 18 consecutive injections of 2 µl of peptide with a 120 s interval between injections, using a stirring rate of 600 rpm. Data acquisition and analysis were performed using MicroCal Origin software (version 7.0).

**Size-Exclusion Chromatography**

Superdex 200 10/300GL column (GE Healthcare) was equilibrated with the buffer containing 20 mM Tris-HCl (pH 8.0) and 100 mM NaCl and calibrated using molecular weight standards, γ-globulin (158 kDa), ovalbumin (45 kDa), myoglobin (17 kDa), and vitamin B12 (1.35 kDa). The purified TplEi and/or TplE-TplEi complex (∼1 mg/ml) was loaded onto the column running at a flowrate of 0.15 ml/min.

**Cell-Toxicity Assay**

Cell-toxicity assay was carried as previously described with minor modification (Jiang et al., 2016). Briefly, *E. coli* BL21 (DE3) strains harboring plasmids expressing periplasmic-targeted TplE, TplE-TplEi and the “L” peptide were grown overnight and serially diluted in LB medium at 10-fold. A 2 µl bacterial dilution was spotted onto LB agar plate containing 0.045 mM IPTG. Images were taken after 24 h growth.

**RESULTS**

**Identification of a Peptide from TplE that Disrupts the TplE-TplEi Complex**

Immunity proteins specifically bind their cognate effectors, thereby neutralizing their hazardous activity, and disrupting the interaction between effectors and immunity proteins represents a potential antibacterial strategy. The goal of this study was to identify a peptide that can specifically bind to the protein interaction interface of TplEi to preclude the formation of the TplE-TplEi complex. The crystal structure of the TplE-TplEi complex (also known as the Tle4−Tli4 complex) was recently solved (Lu et al., 2014). However, the interaction between TplE and TplEi is mediated by numerous hydrophobic contacts, hydrogen bonds or salt-bridges, which involves a large collection of residues and several discrete regions of TplE. It is therefore difficult to predict which regions play a pivotal role in TplEi binding based on this structure.

To identify the region of TplE conferring the strongest binding of the immunity protein, we designed the experiment of *in situ* proteolysis and crystallization (Figure S1A). We first purified and concentrated the TplEi/TplE-TplEi complexes (Figure 1B), and incubated them with trypsin (∼1:2,000 w/w) or subtilisin (∼1:8,000 w/w) prior to crystallization trials. Because regions buried in tight protein-protein interfaces are more resistant to proteolysis than looser structural elements, proteases can digest all but the key fragments essential to the TplE-TplEi interaction, and these fragments can be identified by crystal structure determination. As anticipated, after 30 days of proteolysis and crystallization, we first observed crystals growing from the subtilisin-treated TplE-TplEi complex sample, and crystals diffracted the X rays to 2.2Å (Table 1). We determined the crystal structure using single-wavelength anomalous dispersion (SAD). Because we independently determined this structure before the releasing of Tle4−Tli4 full complex structure (PDB ID: 4R1D), the de novo structure determination using SAD was necessary. Surprisingly, the majority of TplEi was intact, whereas TplE had been degraded except for a 27 residue fragment that remained bound to TplEi (Figure 1A). The electron density for residues 82-108 of TplE is well defined in the final map apart from the head and tail region (Figure S1B). Next, we also obtained crystals of TplEi alone and determined the structure at 3.06 Å resolution using SAD. The TplEi apo structure is very similar with peptide-bound TplEi. Parameters of data collection, structure determination and refinement are summarized in Table 1.

As shown in Figures 1C,D, residues 82-108 of TplE is comprised α1 and α2 helices that are connected by a disordered loop region. Because α1 is significantly longer than α2 and the two helices are nearly perpendicular to each other, the peptide exhibits a “L” shape, thus, we designated it as “L” peptide based on its shape. The “L” peptide accommodates a negatively charged groove of domain II of TplEi (Figure 1D). Using PDBExplorer (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html), we calculated the buried area by “L” peptide (1173.6Å²), accounting for 46.4% of the total surface area of the peptide, and the ΔG value (the solvation free energy gain upon formation of the interface) was −19.6 kcal/mol. By comparison, the surface area buried by the intact TplE in the TplE-TplEi complex is 2,735.5 Å², which is more than double that of the “L” peptide. However, the ΔG of the TplE-TplEi complex is −21.4 kcal/mol, which is not significantly different from that of the TplEi-“L” peptide complex. These results suggest that the region corresponding to the “L” peptide is crucial for the TplE-TplEi interaction, which is consistent with our proteolysis and crystallographic results.

The structure of TplEi alone is very similar to that observed in the peptide-bound form (Figure 1E), with only a handful of side chains with different rotamer conformations (Figure S1C). Specifically, the side chains of residues such as Mse274 move out to avoid clashes, F230 and R209 are closer to the peptide, and residues E219, E211, and K266 change their side chain conformations to form hydrogen bonds or salt bridges with the peptide. The similarity between the free and peptide-bound forms suggests that the TplEi structure is highly compact and rigid, and the “L” peptide binds via a structurally stable pocket on TplEi. We also superimposed the structures of TplEi-“L” peptide complex with TplE-TplEi complex (PDB:4R1D) (Figure 1F). While the structures TplEi are well superimposed, the “L” peptide overlays with the protein interaction interface of the small subdomain of the TplE Cap domain (Figure 1F). The structural superimposition of the “L” peptide and TplE aligned 25 Ca atoms.
FIGURE 1 | The overall structure of TplE peptide and TplEi complex. (A) Structure of the TplE and TplEi proteins. The sequence of TplE peptide digested by subtilisin and TplEi signal peptide are shown. (B) Molecular weight of TplEi and the TplE-TplEi complex assessed by size exclusion chromatography. The Superdex-200 HR 10/300GL column was equilibrated with protein standards γ-globulin 158 kDa, ovalbumin, 44 kDa, myoglobin 17 kDa and vitamin B12, 1.35 kDa. The molecular weights of TplE and TplE-TplEi were calculated as 42 and 105 kDa, respectively. (C) Ribbon diagram representation of TplE peptide-TplEi complex. TplEi (orange) is shown in cartoon representation, and the TplE peptide (green) is also shown in a cartoon representation. (D) Surface electrostatic view of the TplE peptide-TplEi complex with their orientations corresponding to those shown in (C). The peptide (D82-A108 in cartoon representation) binds in the hydrophobic groove of TplEi. (E) Superimposition of the crystal structures of TplEi alone and TplEi-TplE peptide. (F) Superimposition of the crystal structures of TplE-TplE peptide and TplEi-TplE complex (PDB:4R1D).

with a rmsd value of 0.59 Å, indicating that the conformation of the “L” peptide alone is nearly identical to its conformation in the context of the full protein (Figure 1F). Importantly, the mode of interaction between the region corresponding to the “L” peptide and TplEi remains unchanged in the TplE-TplEi complex.
# Table 1: Data collection and refinement statistics.

|                      | TplEi (SeMet derivative) (PDB ID: 5H7Z) | TplEi-TplE (SeMet derivative) (PDB ID: 5H7Y) |
|----------------------|----------------------------------------|---------------------------------------------|
| **DATA COLLECTION**  |                                        |                                             |
| Space group          | I41                                    | P6122                                       |
| Cell dimensions      |                                        |                                             |
| a, b, c (Å)          | 182.23, 182.23, 78.87                   | 113.61, 113.61, 128.13                     |
| α, β, γ (°)          | 90.00, 90.00, 90.00                     | 90.00, 90.00, 120.00                       |
| X-ray source         | SSRF BEAMLINE BL17U                     | SSRF BEAMLINE BL17U                        |
| Wavelength (Å)       | 0.9792 (Se peak)                        | 0.9792 (Se peak)                           |
| Data range (Å)       | 31.25–3.06                             | 34.13–2.20                                 |
| Reflections unique   | 46,474                                 | 47,162                                      |
| $R_{sym}$ (last shell)| 0.624 (0.10)                           | 0.575 (0.09)                               |
| $i/o$ (last shell)   | 14.44 (2.67)                           | 26.69 (5.51)                               |
| Completeness (%)     | 96.9 (81.40)                           | 99.8 (98.80)                               |
| Redundancy (last shell)| 4.28 (3.34)                            | 16.22 (15.00)                              |
| **REFINEMENT**       |                                        |                                             |
| Resolution range (Å) | 31.25–3.06                             | 34.13–2.20                                 |
| Reflections (non-anomalous), cut-off, cross validation | 47,977 (46,474), $F > 1.34$, 2,380 | 47,271 (47,162), $F > 1.34$, 2,397 |
| $R_{work}$/$R_{free}$ (last shell) | 0.2031/0.2448 (0.3308/0.3105) | 0.1948/0.2244 (0.2574/0.2777) |
| **ATOMS**            |                                        |                                             |
| Non-hydrogen protein atoms | 4,834                                  | 2,587                                       |
| Protein              | 4,774                                  | 2,432                                       |
| Ligands              | 0                                      | 0                                           |
| Solvent              | 60                                     | 155                                         |
| B-factors average (Å²) | 70.16                                  | 38.97                                       |
| Protein (Å²)         | 69.98                                  | 38.95                                       |
| Ligands (Å²)         | 0                                      | 0                                           |
| Solvent (Å²)         | 98.10                                  | 39.54                                       |
| r.m.s.d              |                                        |                                             |
| Bond lengths (Å)     | 0.003                                  | 0.012                                       |
| Bond angles (°)      | 0.872                                  | 1.188                                       |
| **VALIDATION**       |                                        |                                             |
| Clash score, all atoms | 4.43                                   | 5.42                                        |
| % Poor rotamers      | 0.78                                   | 0.74                                        |
| % residues in favored regions, allowed regions, and outliers in the Ramachandran plot | 95.44, 4.56, 0 | 97.59, 2.41, 0 |

* $R_{sym} = \sum_{hkl} \sum_{j} |I_{hkl},j| - I_{hkl}|/\sum_{hkl} \sum_{j} I_{hkl},j$, where $I_{hkl}$ is the average of the symmetry-related observations of a unique reflection.
* $R_{work} = \sum_{hkl} |F_{obs}(hkl)| - |F_{calc}(hkl)|/\sum_{hkl} |F_{obs}(hkl)|$.
* $R_{free} =$ the cross-validation $R$ factor for 5% of reflections against which the model was not refined.

## TplE Peptide has High Binding Affinity to TplEi

The crystal structure of TplE peptide-bound TplEi prompted us to speculate that the TplE "L" peptide may have high binding affinity to TplEi and could be a potential inhibitor targeting TplE/TplEi complex. To test our hypothesis, we synthesized two types of "L" peptide: A peptides and B peptides (Figure 2A). Using isothermal titration calorimetry (ITC), we measured a dissociation constant ($K_d$) between A/B peptides and TplEi and evaluated their binding affinity in vitro. Intriguingly, while the dissociation constant ($K_d$) is $\sim 125$ nM between the A peptides and TplEi, the binding affinity of the shorter B peptides decreased with a $K_d = 478$ nM (Figure 2B), therefore only A peptides were used in the following characterizations. Comparing with B peptides, A peptides contain an additional C-terminal 111-VEVDD115 segment. This segment was not observed in the structure of "L" peptide-TplEi complex, indicating that this region does not bind TplEi. The structure of TplE-TplEi complex reported by Lu et al. also shows that 111-VEVDD115 segment is not in contact with the immunity protein. Therefore, the contribution of 111-VEVDD115 segment in binding affinity was unlikely to increase the binding interface. Rather, the original purpose of adding the 111-VEVDD115 segment was to increase charging at the C-terminus of the peptide, therefore it may improve the stability and overall folding of the peptide. The increased binding affinity of A peptides over B peptides seem
FIGURE 2 | ITC analysis of the interaction between the TplE peptide and TplEi. (A) Sequences of A peptides and B peptides derived from TplE peptide crystal structure. B peptides add EQ residues, and A peptides add EQVEVDD residues. (B) The binding affinities of TplE peptide (A peptides and B peptides) to TplE were determined using ITC. The upper part of each panel shows the raw data (top) (thermal power against time), and the bottom part of each panel shows the binding isotherm (normalized heat against molar ratio of reactants) for each injection. The data were fitted to a single-site binding model. The dissociation constants (K_d) are reported at the lower panels. The number of binding sites (N), enthalpy (ΔH), and entropy (ΔS) is also provided.

to support our hypothesis. Collectively, the ITC data suggests that the “L” peptide could occupy the binding interface on TplEi, therefore it is possible that the “L” peptide acts to prevent TplE/TplEi complex formation.

Details of TplE “L” Peptide-TplEi Interaction and Validation by Mutagenesis Studies
Details of the TplE “L” peptide interaction with TplEi involves two salt bridges, eight hydrogen bonds and 147 non-bonded contacts through PDBsum analysis (de Beer et al., 2014) (Figures S2A,B). The “L” peptide adopts a highly extended conformation except for P99 introducing a turn in the C-terminus. The “L” peptide lying across the TplEi domain II area formed a large hydrophobic pocket. As illustrated in Figure 3A, approximately eight direct hydrogen bonds were found between TplEi and the “L” peptide (red dashes). In particular, “L” peptide residue K100 is anchored in the deep pocket (Figures 1D, 3A) through four hydrogen bonds formed with TplEi residues S215, T216, and G217. Three hydrogen bonds are formed between K100 side chain and the carbonyl groups of TplEi residues, and one hydrogen bond is formed between K100 side chain and S215 side chain. We validated the hydrogen bonding contribution by ITC, and the results showed that K100E mutation completely abolished the “L” peptide binding (Figure 3D), stressing the importance of K100 in the “L” peptide binding ability. Two salt bridges were also observed between TplEi and the “L” peptide (blue dashes) (Figure 3B). The side chain of K266 and the side chain of E211 in TplEi are connected to the “L” peptide through two salt bridges with the side chain of residue D83 and the side chain R97 of the “L” peptide, respectively. However, mutation in “L” peptides R97 to opposite charges has no effect on “L” peptide binding (Figure S2C). This result suggests that the salt bridge might not have significant effect on binding ability. TplEi is assembled into a highly rigid structure, not only in the apo but also in the peptide-bound structure. “L” peptide residues D82, D83, L84, F85, S87, I88, L91, W92, A95, G98, P99, L105, and K107 are buried in TplEi surface areas (Figure 3C). To validate the contribution of the hydrophobic interaction to “L” peptide recognition, we performed ITC assay. We found that alanine substitutions of key amino acids in the “L” peptide decreased binding to TplEi, especially for W92A mutation, resulting in a 500-folds reduction in binding affinity. Compared with salt bridge interaction, the hydrophobic interaction plays more important role in “L” peptide binding (Figure 3D). However,
two mutations (W96A and P99A) increased binding affinity compared to WT (Figure 3E); this phenomenon can be explained by the fact that W96 backbone atoms does not affect hydrogen bond formation to TplEi R226, and aromatic group mutation reduced steric hindrance. In contrast, P99A mutation eliminates a turn in the peptide and therefore increases binding affinity. This implies that optimizing the design of the “L” peptide can increase its binding ability.

It is surprising to find that a single mutation (like K100E) of the “L” peptide could abolish the binding with TplEi, regardless of the type of mutation.
that a large area of the peptide is involved in the interaction with the immunity protein. To further elucidate the mechanism underlying the “L” peptide binding, we mutated several key residues of TplEi interacting with the “L” peptide, and measured the binding affinity of the “L” peptide to these TplEi mutants using ITC. The side chain of K100 of the “L” peptide forms four hydrogen bonds with TplEi, among which only one involves side chain interaction with S215 of TplEi, whereas the other three involve backbone atoms. Therefore, we introduced S215A mutation to TplEi, and found that the “L” peptide bound the S215A mutant with the Kd = 7.8 µM, indicating nearly 62-folds reduced binding affinity comparing to the affinity to the wild type TplEi (Kd = 0.125 µM, Figure S3). This data demonstrated that the disruption of a single hydrogen bond could indeed significantly disrupt the interaction of the “L” peptide and TplEi. Similarly, we prepared TplEi mutants E219A and R266A, respectively. E219 forms a hydrogen bond with backbone NH group of K100 of the “L” peptide, and R266 forms two hydrogen bonds with the carbonyl group of W96 of the peptide (Figure 3A). As expected, the binding affinities of the “L” peptide with E219A and R266A mutants reduced significantly. The Kd for E219A and R266A were 35.5 and 46.9 µM, respectively, indicating 284- and 375-folds decreased binding affinities (Figure S3).

The “L” Peptide Displaces the TplE Effector Activator to Induce Autointoxication

As the “L” peptide has high affinity and specificity to TplEi in vitro, we hypothesized that it could function as an activator of TplE by competitive binding to TplEi, which could in turn induce bacterial death in vivo. To test this hypothesis, we performed Escherichia coli cell toxicity assays as previously described (Dong et al., 2013; Jiang et al., 2016). Consistent with the previous report that TplE is an antibacterial lipolytic toxin and TplEi is a cognate periplasmic immunity protein (Jiang et al., 2016), periplasmic expression of TplE in E.coli resulted in a significant inhibition of growth, while co-expression of TplEi repressed the TplE-dependent growth inhibition (Jiang et al., 2016). The role of “L” peptide was further investigated in vivo using this method. As expected, expression of the “L” peptide but not a control peptide resulted in significant TplE-dependent growth inhibition (Figures 4A,B). Consistent with the in vitro data that K100E mutation abolishes and W92A weakens the binding of “L” peptide with TplEi (Figure 3D), expression of the K100E mutated “L” peptide resulted in a strong and expression of another mutated “L” peptide (W92A) resulted in a moderate decreased growth inhibition. Taken together, these results suggested that the “L” peptide could disrupt the TplE-TplEi interaction to release TplE toxicity.

DISCUSSION

The T6SS has recently received much attention because it plays an important role in intra-and inter-species completion between bacteria, and hence in microbial pathogenesis (Durand et al., 2014; Russell et al., 2014; Alcoforado Diniz et al., 2015). TplE, a new T6SS trans-kingdom toxin, targets the conserved and essential cell membranes of rival bacteria to cause bacteriolysis, while TplEi functions as a cognate immunity protein to prevent self-intoxication (Jiang et al., 2016). It would be a powerful antibacterial strategy to release the TplE activity by using small compounds or peptides as inhibitors of the TplE-TplEi interactions. In this study, we identified a TplE “L” peptide upon protease-assisted co-crystallization with TplEi. The TplE “L” peptide displays strong binding affinity to the TplEi protein (Figure 2B), and further analysis showed that binding to TplEi might disrupt the TplE-TplEi interaction and unleash the TplEi toxin to induce bacterial auto-intoxication and autolysis (Figure 5).

The structure of the TplE-TplEi complex reveals that the small subdomain of the TplE Cap domain interacts with domain II of TplEi, whereas the large subdomain of the TplE Cap domain interacts with domain I of TplEi (Lu et al., 2014). Our combined proteolytic and crystallographic experiments showed that the “L” peptide binds specifically to a groove in domain II of TplEi. Our calculations showed that formation of the TplE-TplEi and TplEi-“L” peptide complexes proceeds with similar ΔG values, suggesting that the interaction between the “L” peptide and TplEi...
plays a major role in the formation of the TplE-TplEi complex. This is consistent with the previous report that the groove in domain II of TplEi is important for TplE-TplEi complex formation (Lu et al., 2014). Thus, the occupation of this groove by the “L” peptide might disrupt the TplE-TplEi interaction and release TplE lipase activity.

The targeting of T6SS effector-immunity (E-I) pairs is analogous to toxin-antitoxin (TA) systems, the exploitation of which has received considerable attention as a strategy for developing antibacterial drugs (Lee and Lee, 2016; Kang et al., 2017). For example, several peptide inhibitors based on the Bacillus anthracis PemIK interaction were designed to mimic the antitoxin and release the PemK toxin to kill the bacteria (Agarwal et al., 2010; Barbosa et al., 2012). A naturally occurring quorum sensing (QS) pentapeptide EDF from the E. coli MazE-MazF TA system competitively interacts with the MazE-binding site for MazF, and thereby overcomes the inhibitory activity of the antitoxin MazE, releasing the MazF toxin and ultimately causing cell death (Belitsky et al., 2011). Based on the structure of the VapB-VapC complex in Mycobacterium tuberculosis, several kinds of peptides mimicking the toxin and antitoxin were designed to disrupt the TA interaction and activate the ribonuclease activity of the VapC toxin (Lee et al., 2015; Kang et al., 2017), providing a novel antibacterial approach to the development of new antibiotics.

The TplE “L” peptide is an example of a toxin-mimicking peptide that binds to TplEi and disrupts the TplE-TplEi interaction, releasing the active TplE toxin. However, further work is needed to assess the potential of the “L” peptide for treating P. aeruginosa infections. For example, we only tested the efficacy of the “L” peptide against E. coli, and whether the expression of the peptide would affect the growth of P. aeruginosa still needs to be verified. In addition, the TplE “L” peptide must access the periplasm to disrupt the TplE-TplEi interaction, which could prove difficult, although cell-penetrating peptides (CPPs) attached to the TplE “L” peptide could potentially overcome this drawback to provide a novel therapeutic agent (Fosgerau and Hoffmann, 2015). Nevertheless, the present study provides a structural and biochemical basis for the development of antibacterial peptides, and provides a proof of concept for structure-based design and targeting of the T6SS in P. aeruginosa and other bacteria. The TplE “L” peptide represents a novel drug candidate for a T6SS-based therapeutic strategy against P. aeruginosa.

ACCESSION CODES

The atomic coordinates and structure factors have been deposited in the Protein Data Bank with the accession codes 5H7Z for TplE and 5H7Y for TplE peptide-TplEi.

AUTHOR CONTRIBUTIONS

SC, YS, and XG designed the study. SC, YS, and XG wrote the paper. XG and ZM purified and crystallized protein and determined structure. XG and ZM performed and analyzed ITC assay, Cell-toxicity assay. BQ designed construct for expression of protein. All authors reviewed the results and approved the final version of the manuscript.

FUNDING

This work was supported by National Natural Science Foundation of China [81401714]; Beijing Natural Science Foundation [7154226]; CAMS Innovation Fund for Medical Sciences; PUMC Youth Fund and the Fundamental Research Funds for the Central Universities [3332015097]; The
ACKNOWLEDGMENTS

We thank Shanghai Synchrotron Radiation Facility (SSRF) beamline BL17U for beam time allowance and help with data collection. We thank the Tsinghua University Branch of China's National Science and Technology Major Project of China [2013ZX10004601].

REFERENCES

Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221. doi: 10.1107/S0907444909052925

Agarwal, S., Mishra, N. K., Bhatnagar, S., and Bhatnagar, R. (2010). PemK toxin of Bacillus anthracis is a ribonuclease: an insight into its active site, structure, and function. J. Biol. Chem. 285, 7254–7270. doi: 10.1074/jbc.M110.073387

Alcoforado Diniz, J., Liu, Y. C., and Coulthurst, S. J. (2015). Molecular weaponry: diverse effectors delivered by the Type VI secretion system. Cell Microbiol. 17, 1742–1751. doi: 10.1111/cmi.12532

Barbosa, L. C. B., Garrido, S. S., Garcia, A., Delfino, D. B., Santos, L. D. N., and Marchetto, R. (2012). Design and synthesis of peptides from bacterial PapE toxin as inhibitors of topoisomerases. Eur. J. Med. Chem. 54, 591–596. doi: 10.1016/j.ejmech.2012.06.008

Belitsky, M., Avshalom, H., Erental, A., Yelin, I., Kumar, S., London, N., et al. (2011). The Excherichia coli extracellular death factor EDF induces the endoribonucleolytic activities of the toxins MazF and ChtpR. Mol. Cell. 41, 625–635. doi: 10.1016/j.molcel.2011.02.023

Bricogne, G., vonrhein, C., Flensburg, C., Schiltz, M., and Paciorek, W. (2003). Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. Acta Crystallogr. D Biol. Crystallogr. 59, 2023–2030. doi: 10.1107/S090744490317694

Cianfanelli, F. R., Monleuzin, L., and Coulthurst, S. J. (2016). Aim, load, fire: the Type VI secretion system, a bacterial nanoweapon. Trends Microbiol. 24, 51–62. doi: 10.1016/j.tim.2015.10.005

de Beer, T. A., Berka, K., Thornton, J. M., and Laskowski, R. A. (2014). PDBsum additions. Nucleic Acids Res. 42, D292–D296. doi: 10.1093/nar/gkt940

Dong, C., Zhang, H., Gao, Z. Q., Wang, W. J., She, Z., Liu, G. F., et al. (2013). Structural insights into the inhibition of type VI effector Tai3 by its immunity protein Tai3. Biochem. J. 454, 59–68. doi: 10.1042/BJ20130193

Durand, E., Cambillau, C., Cascales, E., and Journet, L. (2014). VgR, Tae, Tle, and Tai3. Biochem. J. 454, 59–68. doi: 10.1042/BJ20130193

Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132. doi: 10.1107/S090744490419158

Fosterau, K., and Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122–128. doi: 10.1016/j.drudis.2014.10.003

Jiang, F., Wang, X., Wang, B., Chen, L., Zhao, Z., Waterfield, N. R., et al. (2016). The Pseudomonas aeruginosa Type VI secretion system effectors: poisons with a purpose. Trends Microbiol. 24, 498–507. doi: 10.1016/j.tim.2014.06.004

Kabsch, W. (2010). Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132. doi: 10.1107/S0907444910019337

Kang, S. M., Kim, D. H., Lee, K. Y., Park, S. J., Yoon, H. J., Lee, S. J., et al. (2017). Functional details of the Mycobacterium tuberculosis VapBC26 toxin-antitoxin system based on a structural study: insights into unique binding and antibio tic peptides. Nucleic Acids Res. 45, 8564–8580. doi: 10.1093/nar/gkx489

Lee, I. G., Lee, S. J., Chae, S., Lee, K. Y., Kim, J. H., and Lee, B. J. (2015). Structural and functional studies of the Mycobacterium tuberculosis VapBC30 toxin-antitoxin system: implications for the design of novel antimicrobacterial peptides. Nucleic Acids Res. 43, 7624–7637. doi: 10.1093/nar/gkv689

Lee, K. Y., and Lee, B. J. (2016). Structure, biology, and therapeutic application of toxin-antitoxin systems in pathogenic bacteria. Toxins 8:305. doi: 10.3390/toxins8100305

Lu, D., Zheng, Y., Liao, N., Wei, L., Xu, B., Liu, X., et al. (2014). The structural basis of the Tle4-Tl4 complex reveals the self-protection mechanism of H2-TeSS in Pseudomonas aeruginosa. Acta Crystallogr. D Biol. Crystallogr. 70, 3233–3243. doi: 10.1107/S1995000114023967

Oliver, A., Mulet, X., Lopez-Casaspe, C., and Juan, C. (2015). The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist. Update 21-22, 41–59. doi: 10.1016/j.drup.2015.08.002

Sana, T. G., Berni, B., and Bleves, S. (2016). The T6SSs of Pseudomonas aeruginosa Strain PAO1 and their effectors beyond bacterial-cell targeting. Front. Cell Infec. Microbiol. 6:61. doi: 10.3389/fcimb.2016.00061

Shneider, M. M., Buth, S. A., Ho, B. T., Basler, M., Mekalanos, J. J., and Leiman, P. G. (2013). PAAR-repeat proteins sharpen and diversify the type VI secretion system spike. Nature 500, 350–353. doi: 10.1038/nature12453

Silverman, J. M., Agnelo, D. M., Zheng, H., Andrews, B. T., Li, M., Catalano, C. E., et al. (2013). Haemolysin coregulated protein is an exported receptor and chaperone of type VI secretion substrates. Mol. Cell 51, 584–593. doi: 10.1016/j.molcel.2013.07.025

Whitney, J. C., Beck, C. M., Goo, Y. A., Russell, A. B., Harding, B. N., De Leon, J. A., et al. (2014). Genetically distinct pathways guide effector export through the type VI secretion system. Mol. Microbiol. 92, 529–542. doi: 10.1111/mmi.12571

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Gao, Mu, Qin, Sun and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.